DSUVIA

Peak

sufentanil

NDASUBLINGUALTABLET
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

Full Opioid Agonists

Pharmacologic Class:

Opioid Agonist

Clinical Trials (2)

NCT05288348Phase 3Completed

DSUVIA Early Evaluation of Pain Trial

Started Aug 2022
150 enrolled
Traumatic Injury
NCT00421720Phase 4Terminated

A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.

Started Jan 2007
164 enrolled
AnalgesiaSedation

Loss of Exclusivity

LOE Date
Feb 2, 2038
145 months away
Patent Expiry
Feb 2, 2038

Patent Records (5)

Patent #ExpiryTypeUse Code
9744129
Jan 5, 2027
Product
10342762
Jan 5, 2027
Product
10507180
Jan 5, 2027
Product
U-1351
8252328
Jan 5, 2027
Product
8252329
Jan 5, 2027
Product